EP0831854A4 - Oligonukleotide mit phosphorothioat-bindungen von hoher chiraler reinheit - Google Patents

Oligonukleotide mit phosphorothioat-bindungen von hoher chiraler reinheit

Info

Publication number
EP0831854A4
EP0831854A4 EP96921270A EP96921270A EP0831854A4 EP 0831854 A4 EP0831854 A4 EP 0831854A4 EP 96921270 A EP96921270 A EP 96921270A EP 96921270 A EP96921270 A EP 96921270A EP 0831854 A4 EP0831854 A4 EP 0831854A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotides
phosphorothioate linkages
chiral purity
high chiral
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96921270A
Other languages
English (en)
French (fr)
Other versions
EP0831854A1 (de
Inventor
Phillip Dan Cook
Glenn Hoke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/468,569 external-priority patent/US5620963A/en
Priority claimed from US08/471,966 external-priority patent/US5661134A/en
Priority claimed from US08/468,447 external-priority patent/US5576302A/en
Priority claimed from US08/469,851 external-priority patent/US5587361A/en
Priority claimed from US08/467,597 external-priority patent/US5607923A/en
Priority claimed from US08/471,967 external-priority patent/US5599797A/en
Priority claimed from US08/466,692 external-priority patent/US5654284A/en
Priority claimed from US08/470,129 external-priority patent/US5635488A/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP0831854A1 publication Critical patent/EP0831854A1/de
Publication of EP0831854A4 publication Critical patent/EP0831854A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96921270A 1995-06-06 1996-06-05 Oligonukleotide mit phosphorothioat-bindungen von hoher chiraler reinheit Withdrawn EP0831854A4 (de)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US467597 1983-02-18
US468569 1990-01-23
US468447 1995-06-06
US08/468,569 US5620963A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US471966 1995-06-06
US08/471,966 US5661134A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US08/468,447 US5576302A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US08/469,851 US5587361A (en) 1991-10-15 1995-06-06 Oligonucleotides having phosphorothioate linkages of high chiral purity
US08/467,597 US5607923A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US466692 1995-06-06
US470129 1995-06-06
US08/471,967 US5599797A (en) 1991-10-15 1995-06-06 Oligonucleotides having phosphorothioate linkages of high chiral purity
US471967 1995-06-06
US08/466,692 US5654284A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US08/470,129 US5635488A (en) 1991-10-15 1995-06-06 Compounds having phosphorodithioate linkages of high chiral purity
PCT/US1996/008757 WO1996039154A1 (en) 1995-06-06 1996-06-05 Oligonucleotides having phosphorothioate linkages of high chiral purity
US469851 1999-12-22

Publications (2)

Publication Number Publication Date
EP0831854A1 EP0831854A1 (de) 1998-04-01
EP0831854A4 true EP0831854A4 (de) 2001-01-24

Family

ID=27575447

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921270A Withdrawn EP0831854A4 (de) 1995-06-06 1996-06-05 Oligonukleotide mit phosphorothioat-bindungen von hoher chiraler reinheit

Country Status (6)

Country Link
EP (1) EP0831854A4 (de)
JP (3) JPH10510433A (de)
AU (1) AU698739B2 (de)
CA (1) CA2223103A1 (de)
NO (1) NO975558L (de)
WO (1) WO1996039154A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
WO1999005160A2 (en) * 1997-07-25 1999-02-04 Hybridon, Inc. Oligonuclotides having 3' terminal stereospecific phosphorothioates
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
CA2333854A1 (en) * 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereoisomers of cpg oligonucleotides and related methods
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
KR100991975B1 (ko) * 2001-05-16 2010-11-04 미게닉스 인코포레이티드 핵산을 기본으로 하는 화합물 및 이의 사용방법
EP1412750B1 (de) 2001-06-26 2012-05-23 Senomyx, Inc. Heterooligomere t1r2-t1r3 Süssegeschmacksrezeptoren und diese exprimierende Zellinien sowie Verwendung davon zur Identifizierung von Süssegeschmacksverbindungen
US6916621B2 (en) 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
AU2003243157C1 (en) 2002-04-19 2008-09-04 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
EP3023498B1 (de) 2003-03-06 2018-11-28 BASF Enzymes LLC Amylasen, nukleinsäuren zur codierung davon und verfahren zur herstellung und verwendung davon
EP3299465A1 (de) 2003-03-07 2018-03-28 DSM IP Assets B.V. Hydrolasen, nukleinsäuren zur codierung davon und verfahren zur herstellung und verwendung davon
CA2521402C (en) 2003-04-04 2015-01-13 Diversa Corporation Pectate lyases, nucleic acids encoding them and methods for making and using them
CN108486086A (zh) 2003-07-02 2018-09-04 维莱尼姆公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
RU2006106920A (ru) 2003-08-06 2007-09-20 Синомикс Инк. (Us) Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения
US7741089B2 (en) 2003-08-11 2010-06-22 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
CN101432292B (zh) 2004-06-16 2013-03-13 维莱尼姆公司 对叶绿素进行酶促脱色的组合物和方法
WO2006025995A2 (en) 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions and methods using md-2 mutants and chimeric proteins
EP1869174B1 (de) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase-enzyme, nukleinsäuren zu deren kodierung und verfahren zu deren herstellung und verwendung
NZ561247A (en) 2005-03-15 2010-06-25 Verenium Corp Beta-glucosidases, nucleic acids encoding them and methods for making and using them
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US20070059747A1 (en) 2005-09-02 2007-03-15 Regents Of The University Of California Methods and probe combinations for detecting melanoma
EP2216403A3 (de) 2006-02-02 2010-11-24 Verenium Corporation Esterasen und dazugehörige Nukleinsäuren und Verfahren
WO2007094852A2 (en) 2006-02-10 2007-08-23 Verenium Corporation Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
CA2638801C (en) 2006-02-14 2016-12-13 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
CA2643416C (en) 2006-03-07 2016-07-26 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP3153580A3 (de) 2006-03-07 2017-04-19 BASF Enzymes LLC Aldolasen, nukleinsäuren zur codierung davon sowie verfahren zur herstellung und verwendung davon
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
AU2007356171B8 (en) 2006-08-04 2014-01-16 Bp Corporation North America Inc. Glucanases, nucleic acids encoding them, and methods for making and using them
EP2057178B1 (de) 2006-09-21 2013-11-06 Verenium Corporation Phytasen, dafür kodierende nukleinsäuren sowie verfahren zu deren herstellung und verwendung
PL2057274T3 (pl) 2006-09-21 2014-05-30 Dsm Ip Assets Bv Fosfolipazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania
DK2479267T3 (en) 2006-12-21 2017-03-27 Basf Enzymes Llc Amylases and Glucoamylases, Nucleic Acids Encoding Them, and Methods for Preparing and Using Them
AR065544A1 (es) 2007-01-30 2009-06-17 Verenium Corp Enzimas para el tratamiento de lignocelulosicos acidos nucleicos que las codifican y metodos para prepararlas y usarlas
AU2008245611B2 (en) 2007-04-27 2014-09-18 University Of California Plant CO2 sensors, nucleic acids encoding them, and methods for making and using them
AU2008307371B2 (en) 2007-10-03 2015-05-28 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
EP2959917A3 (de) 2007-10-19 2016-02-24 The Regents of The University of California Zusammensetzungen und verfahren zur linderung von entzündungen des zns, psychose, delirium, ptsd oder ptss
ES2531290T3 (es) 2008-01-03 2015-03-12 Basf Enzymes Llc Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
WO2009088753A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2010019696A2 (en) 2008-08-12 2010-02-18 Allylix, Inc. Method for production of isoprenoids
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
CA2734922C (en) 2008-09-15 2020-01-14 Laetitia Malphettes Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
JP6101077B2 (ja) 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
KR101817253B1 (ko) 2009-05-21 2018-01-10 신젠타 파티서페이션즈 아게 피타제, 이를 코딩하는 핵산 및 그의 제조 및 사용 방법
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
US20120121589A1 (en) 2009-07-13 2012-05-17 Wayne State University Modified egfr ectodomain
DK2462165T3 (en) 2009-08-03 2016-08-29 Univ Miami Method for in vivo proliferation of regulatory T cells
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
US20120277112A1 (en) 2009-10-19 2012-11-01 Stichting Het Nederlands Kanker Instituut Predicting response to anti-cancer therapy via array comparative genomic hybridization
US20120322677A1 (en) 2009-10-19 2012-12-20 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
US20120316080A1 (en) 2009-10-19 2012-12-13 Stichting Het Nederlands Kanker Instiuut Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization
JP2013507989A (ja) 2009-10-26 2013-03-07 アボット・ラボラトリーズ 非小細胞肺癌の予後に関連する染色体異常の検出
JP5985397B2 (ja) 2009-11-11 2016-09-06 アドバクシス インコーポレイテッド 組換えリステリア株およびそれを含む免疫原性組成物
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20120065085A1 (en) 2010-05-10 2012-03-15 Abbott Laboratories Detection of chromosomal abnormalities associated with endometrial cancer
WO2012038837A2 (en) 2010-09-20 2012-03-29 Stichting Het Nederlands Kanker Instituut Methods for predicting response to anti-cancer therapy in cancer patients
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US9096871B2 (en) 2010-10-06 2015-08-04 Bp Corporation North America Inc. Variant CBH I polypeptides with reduced product inhibition
US8969254B2 (en) 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013124740A2 (en) 2012-02-23 2013-08-29 Stichting Vu-Vumc BRCA DEFICIENCY PROTEIN AND mRNA SIGNATURES USEFUL IN IDENTIFICATION OF PATIENTS WITH BRCA-DEFICIENT TUMORS AND PREDICTING BENEFIT OF ANTI-CANCER THERAPY IN CANCER PATIENTS
JP2015511602A (ja) 2012-03-12 2015-04-20 アドバクシス， インコーポレイテッド リステリアワクチン処理後のサプレッサー細胞機能抑制
AU2013266243A1 (en) 2012-05-24 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
AU2013278070B2 (en) 2012-06-22 2019-07-11 The Regents Of The University Of California Compositions and methods for mediating plant stomatal development in response to carbon dioxide and applications for engineering drought tolerance in plants
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
EP2873674B1 (de) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Adjuvans für chirale nukleinsäure
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
ES2757623T3 (es) 2012-07-25 2020-04-29 Broad Inst Inc Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
EP2931892B1 (de) 2012-12-12 2018-09-12 The Broad Institute, Inc. Verfahren, modelle, systeme und vorrichtungen zur identifikation von zielsequenzen für cas-enzyme oder crispr-cas-systeme für zielsequenzen und förderresultate davon
EP2931899A1 (de) 2012-12-12 2015-10-21 The Broad Institute, Inc. Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
PL2896697T3 (pl) 2012-12-12 2016-01-29 Broad Inst Inc Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją
PL2898075T3 (pl) 2012-12-12 2016-09-30 PROJEKTOWANIE i OPTYMALIZACJA ULEPSZONYCH SYSTEMÓW, SPOSOBY I KOMPOZYCJE ENZYMÓW DO MANIPULACJI SEKWENCJĄ
EP2943253B1 (de) 2013-01-09 2021-10-20 University Of Miami Zusammensetzungen und verfahren zur regulierung regulatorischer t-zellen mit tl1a-ig-fusionsprotein und il-2
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
KR20160034901A (ko) 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 ｃｒｉｓｐｒ-ｃａｓ 이중 닉카아제 시스템, 방법 및 조성물
CN105793425B (zh) 2013-06-17 2021-10-26 布罗德研究所有限公司 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
EP3011029B1 (de) 2013-06-17 2019-12-11 The Broad Institute, Inc. Bereitstellung, technische konzeption und optimierung von tandemführungssystemen, verfahren und zusammensetzungen zur sequenzmanipulation
CN107995927B (zh) 2013-06-17 2021-07-30 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
ES2767318T3 (es) 2013-06-17 2020-06-17 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
WO2015057671A1 (en) 2013-10-14 2015-04-23 The Broad Institute, Inc. Artificial transcription factors comprising a sliding domain and uses thereof
EP3058091B1 (de) 2013-10-18 2020-03-25 The Broad Institute, Inc. Räumliche und zelluläre kartographie von biomolekülen in situ durch hochdurchsatz-sequenzierung
EP3080259B1 (de) 2013-12-12 2023-02-01 The Broad Institute, Inc. Konstruktion von systemen, verfahren und optimierte führungszusammensetzungen mit neuen architekturen zur sequenzmanipulation
KR20160089527A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
JP2017501149A (ja) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
CA2932472A1 (en) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
AU2014361784A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
EP3095461A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
EP3095459A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
EP3107935B1 (de) 2014-02-20 2020-06-24 Allergan, Inc. Antikörper der komplementkomponente c5
CA2939586A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
CN109207580B (zh) 2014-03-12 2022-03-11 西奈山伊坎医学院 鉴定处于慢性损伤风险的肾异体移植物接受者的方法
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
AU2015279542B2 (en) 2014-06-26 2021-07-29 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
MA40344A (fr) 2014-07-18 2016-01-21 Advaxis Inc Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
DK3180426T3 (da) 2014-08-17 2020-03-30 Broad Inst Inc Genomredigering ved anvendelse af cas9-nickaser
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3985115A1 (de) 2014-12-12 2022-04-20 The Broad Institute, Inc. Geschützte guide-rnas (pgrnas)
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
JP6689279B2 (ja) * 2014-12-16 2020-05-20 ロシュ イノベーション センター コペンハーゲン エーエス キラル毒性のスクリーニング方法
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016191358A1 (en) 2015-05-22 2016-12-01 The Regents Of The University Of California Determining risk of prostate cancer recurrence
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
CA3012631A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3436575A1 (de) 2015-06-18 2019-02-06 The Broad Institute Inc. Neuartige crispr-enzyme und -systeme
WO2016205745A2 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
US20170211142A1 (en) 2015-10-22 2017-07-27 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017075292A1 (en) 2015-10-28 2017-05-04 The Broad Institute, Inc. Systems and methods for determining relative abundances of biomolecules
WO2017075294A1 (en) 2015-10-28 2017-05-04 The Board Institute Inc. Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
CA3026055A1 (en) 2016-04-19 2017-10-26 The Broad Institute, Inc. Novel crispr enzymes and systems
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
EP3445856A1 (de) 2016-04-19 2019-02-27 The Broad Institute Inc. Neuartige crispr-enzyme und -systeme
KR20230156150A (ko) 2016-06-17 2023-11-13 더 브로드 인스티튜트, 인코퍼레이티드 제vi형 crispr 오솔로그 및 시스템
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
SG10201913505WA (en) 2016-10-17 2020-02-27 Univ Nanyang Tech Truncated crispr-cas proteins for dna targeting
EP4361261A3 (de) 2017-03-15 2024-07-10 The Broad Institute Inc. Neuartige cas13b-orthologe crispr-enzyme und systeme
KR20200006054A (ko) 2017-04-12 2020-01-17 더 브로드 인스티튜트, 인코퍼레이티드 신규 타입 vi crispr 오르소로그 및 시스템
US20210278416A1 (en) 2017-05-09 2021-09-09 The Broad Institute, Inc. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
RU2769475C2 (ru) 2017-06-23 2022-04-01 Инскрипта, Инк. Направляемые нуклеиновыми кислотами нуклеазы
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2019113506A1 (en) 2017-12-07 2019-06-13 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
CN112236137B (zh) 2018-04-16 2024-10-01 西奈山伊坎医学院 利用移植前接受者血液中转录组标志预测急性排斥反应和肾脏同种异体移植物丧失的方法和试剂盒
WO2020018166A1 (en) 2018-07-16 2020-01-23 The Regents Of The University Of Michigan Nuclease-mediated nucleic acid modification
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
JP2022544688A (ja) 2019-08-16 2022-10-20 マサチューセッツ インスティテュート オブ テクノロジー Ｃｒｉｓｐｒ／ｃａｓ１３を使用する標的化トランススプライシング
EP4171199A1 (de) 2020-06-25 2023-05-03 Mycotechnology, Inc. Süsses protein aus trüffel
US11248265B1 (en) 2020-11-19 2022-02-15 Clear Labs, Inc Systems and processes for distinguishing pathogenic and non-pathogenic sequences from specimens
JP2023551404A (ja) 2020-11-20 2023-12-08 レビビコア， インコーポレイテッド 異種間移植のための成長ホルモン受容体ノックアウトを有する多重トランスジェニックブタ
US20230045095A1 (en) 2021-06-23 2023-02-09 Massachusetts Institute Of Technology Compositions, Methods and Systems for the Delivery of Gene Editing Material to Cells
US20230255185A1 (en) 2021-09-20 2023-08-17 Revivicor, Inc. Multitransgenic pigs comprising ten genetic modifications for xenotransplantation
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023185697A2 (en) 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
GB202208575D0 (en) 2022-06-13 2022-07-27 Univ Edinburgh Activation of noncoding host gene loci
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024061296A2 (en) 2022-09-22 2024-03-28 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003139A1 (en) * 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
WO1993008296A1 (en) * 1991-10-15 1993-04-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
WO1995002069A1 (en) * 1993-07-09 1995-01-19 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506212A (en) * 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003139A1 (en) * 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
WO1993008296A1 (en) * 1991-10-15 1993-04-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
WO1995002069A1 (en) * 1993-07-09 1995-01-19 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALT M ET AL: "SPECIFIC INHIBITION OF HEPATITIS C VIRAL GENE EXPRESSION BY ANTISENSE PHOPHOROTHIOATE OLIGODEOXYNUCLEOTIDES", HEPATOLOGY, vol. 22, no. 3, 1 September 1995 (1995-09-01), pages 707 - 717, XP000603288, ISSN: 0270-9139 *
MIZUTANI T ET AL: "INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ANTISENSE OLIGONUCLEOTIDE IN CULTURE CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 212, no. 3, 26 July 1995 (1995-07-26), pages 906 - 911, XP000604711, ISSN: 0006-291X *
MONIA B P ET AL: "ANTITUMOR ACTIVITY OF A PHOSPHOROTHIOATE ANTISENSE OLIGODEOXYNUCLEOTIDE TARGETED AGAINST C-RAF KINASE", NATURE MEDICINE, vol. 2, no. 6, 6 June 1996 (1996-06-06), pages 668 - 675, XP002073792, ISSN: 1078-8956 *
See also references of WO9639154A1 *
SEKI MAKOTO ET AL: "Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: In vitro translation assay.", JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 118, no. 6, December 1995 (1995-12-01), pages 1199 - 1204, XP002145739, ISSN: 0021-924X *
STEC W J ET AL: "NOVEL ROUTE TO OLIGODEOXYRIBONUCLEOSIDE PHOSPHOROTHIOATES STEREOCONTROLLED SYNTHESIS OF P-CHIRAL OLIGODEOXYRIBONUCLEOSIDE PHOSPHOROTHIOATES", NUCLEIC ACIDS RESEARCH, vol. 19, no. 21, 1991, pages 5883 - 5888, XP002145738, ISSN: 0305-1048 *
VAKITA T ET AL: "SPECIFIC INHIBITION OF HEPATITIS C VIRUS EXPRESSION BY ANTISENSE OLIGODEOXYNUCLEOTIDES : IN VITRO MODEL FOR SELECTION OF TARGET SEQUENCE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 19, 13 May 1994 (1994-05-13), pages 14205 - 14210, XP000604710, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO1996039154A1 (en) 1996-12-12
NO975558D0 (no) 1997-12-02
CA2223103A1 (en) 1996-12-12
AU6252896A (en) 1996-12-24
JP2001103987A (ja) 2001-04-17
JP2001114798A (ja) 2001-04-24
JPH10510433A (ja) 1998-10-13
EP0831854A1 (de) 1998-04-01
NO975558L (no) 1998-01-26
AU698739B2 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
EP0831854A4 (de) Oligonukleotide mit phosphorothioat-bindungen von hoher chiraler reinheit
AU8938098A (en) Liposomes containing oligonucleotides
AU3775593A (en) Process for preparing phosphorothioate oligonucleotides
AU3222795A (en) Antitumor antisense oligonucleotides
AU4514696A (en) Synthesis of stereospecific oligonucleotide phosphorothioates
AU5441896A (en) Cooperative oligonucleotides
AU2317095A (en) Dna sequences
IL135514A0 (en) Process to make chiral compounds
AU2880392A (en) Chromatographic separation of phosphorothioate oligonucleotides
EP0832896A4 (de) Phosphonatnukleotid-derivate
AU3143695A (en) Improved methods of detritylation for oligonucleotide synthesis
AU6614198A (en) Purification process
HUP9801687A3 (en) Process for producing nucleic acids
EP0750058A3 (de) Dotieren von kristallinen Substraten
GB9502870D0 (en) Chiral compounds
AU3234895A (en) 5'-dithio-modified oligonucleotides
AU3126595A (en) Antisense oligonucleotides of pleiotrophin
GB9526218D0 (en) DNA Sequences
HUT77435A (hu) Aminosavat tartalmazó nukleotid monomer analógok
GB9623876D0 (en) Chiral dopes
ZA956809B (en) Purification of pentafluoroethane
AU5218196A (en) Purification of pentafluoroethane
GB2316076B (en) Chiral Compounds
GB9525496D0 (en) Racemisation
AU9463498A (en) Nucleotide compounds and method of synthesizing oligonucleotides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOKE, GLENN

Inventor name: COOK, PHILLIP, DAN

A4 Supplementary search report drawn up and despatched

Effective date: 20001208

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041224

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.